Benralizumab After Sub-optimal Response to Mepolizumab in Severe Eosinophilic Asthma. Kavanagh J, Hearn A, d'Ancona G, Dhariwal J, et al. Allergy 2020 Dec 9. doi: 10.1111/all.14693.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kavanagh J, Hearn A, d'Ancona G, Dhariwal J, et al. Benralizumab After Sub-optimal Response to Mepolizumab in Severe Eosinophilic Asthma. Allergy 2020 Dec 9. doi: 10.1111/all.14693.
PMID: 33300186